Clinical Trial Search

Primary: Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20). — 28.3; 30.7; 18.1; 42.8 Percentage of participants — p=0.0458

Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 9.2; 3.8 months — p=<0.000001

Primary: Average Rhinoconjunctivitis Total Symptom Score — 4.72; 3.58; 3.74; 4.93 Units on a scale (range: 0 to 18) — p=0.0006

Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) in Study Eye — 5.7; 2.9 letters — p=0.0111

Primary: Change From Baseline in the Brief Pain Inventory (BPI) 24-hour Average Pain Score — -2.23; -1.73 units on a scale

Primary: Average Adjusted Symptom Score (AAdSS) During the Year 1 Primary Period — 3.18; 3.09; 3.87 Units on a scale (range: 0 to 12) — p=0.0066

Primary: Clinical Success — 55.2; 39.2 percentage of Participants — p=0.001

Primary: Combined Score (CS) — 0.32; 0.45 Units on a scale (range: 0 to 3) — p=0.0003

Primary: Number of New Tooth Root Caries Lesions — 1.1; 0.43; 0.56 new carious root surfaces

Primary: Number of Participants With Aggression as Determined by the Cohen-Mansfield Agitation Inventory (Aggression Subscale) — 8; 14; 9; 17 participants — p=0.13

Primary: Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (17-items) at Week 8 and Week 12. — 8; 8.3; 8.9; 7.9 units on a scale

Primary: Clinical Success — 34.8; 19.2; 37.7 percentage of participants — p=0.003

Primary: Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb or Within Target Range During the Efficacy Evaluation Period (EEP)…

Primary: Percentage of Participants in Categories of Change in Weight From Study P06124 Baseline to Final Assessment — 12.9; 26.8; 64.5; 61.6 percentage of participants in category

Primary: Rate of COPD Exacerbations — 3.59; 4.03 COPD Exacerbations/year — p=0.003